SEC Filing Summary: Coeptis Therapeutics Holdings, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on March 21, 2025. The registrant is a Delaware corporation with principal executive offices in Wexford, Pennsylvania. The company's common stock (COEP) and warrants (COEPW) trade on the Nasdaq Capital Market. The filing reports a specific corporate governance event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the departure of a senior executive:
- Resignation: Colleen Delaney resigned as Chief Scientific and Medical Officer.
- Effective Date: March 24, 2025.
- Reason: To pursue another business opportunity.
- Transition: Ms. Delaney will provide consulting services for up to six months to ensure a smooth transition.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the operational impact of the executive departure. The company has not disclosed any unusual items or contingencies in this report.
Investor Verification Checklist
- Verify the appointment of a replacement Chief Scientific and Medical Officer to ensure continuity in clinical development.
- Confirm the terms of the consulting agreement regarding the six-month transition period.
- Review subsequent filings for any impact on the company's clinical trial timelines or regulatory strategy.
- Check the company's latest 10-K or 10-Q for the most recent financial position, as this 8-K contains no financial data.